The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment

Endocrine. 2019 Jun;64(3):441-455. doi: 10.1007/s12020-019-01919-

Guañabens N, Moro-Álvarez MJ, Casado E, Blanch-Rubió J, Gómez-Alonso C, Díaz-Guerra GM, Del Pino-Montes J, Díaz de Lamadrid CV, Peris P, Muñoz-Torres M; SEIOMM Working Group

https://www.ncbi.nlm.nih.gov/pubmed/30963388

Patrocinadores de la web
Lilly
Angelini
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter